Qualigen Therapeutics Faces Nasdaq Delisting Warning
Ticker: AIXC · Form: 8-K · Filed: Aug 5, 2024 · CIK: 1460702
Sentiment: bearish
Topics: delisting-warning, nasdaq, compliance
Related Tickers: QQQ
TL;DR
Nasdaq says Qualigen's stock price is too low, giving them until Jan 29, 2025 to fix it or get booted.
AI Summary
Qualigen Therapeutics, Inc. received a notification on August 2, 2024, indicating it failed to meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company has 180 calendar days, until January 29, 2025, to regain compliance by achieving a minimum closing bid price of $1.00 per share for at least 10 consecutive business days.
Why It Matters
Failure to regain compliance could result in Qualigen Therapeutics' common stock being delisted from the Nasdaq Capital Market, potentially impacting its liquidity and investor confidence.
Risk Assessment
Risk Level: high — The company is at high risk because it has failed to meet a continued listing standard on the Nasdaq, specifically the minimum bid price requirement, and faces a strict deadline to rectify the situation.
Key Numbers
- $1.00 — Minimum Bid Price (Required for continued listing on Nasdaq)
- 180 days — Compliance Period (Timeframe to regain compliance)
- January 29, 2025 — Compliance Deadline (End of the compliance period)
Key Players & Entities
- Qualigen Therapeutics, Inc. (company) — Registrant
- Nasdaq Capital Market (company) — Listing Exchange
- August 2, 2024 (date) — Notification Date
- January 29, 2025 (date) — Compliance Deadline
- $1.00 (dollar_amount) — Minimum Bid Price Requirement
FAQ
What specific rule did Qualigen Therapeutics fail to meet for Nasdaq listing?
Qualigen Therapeutics failed to meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market, which requires a closing bid price of at least $1.00 per share.
When did Qualigen Therapeutics receive the notification of non-compliance?
The company received the notification on August 2, 2024.
How much time does Qualigen Therapeutics have to regain compliance with the Nasdaq listing standards?
Qualigen Therapeutics has 180 calendar days from the date of the notification, until January 29, 2025, to regain compliance.
What is the minimum closing bid price required to regain compliance?
The company must achieve a minimum closing bid price of $1.00 per share for at least 10 consecutive business days.
What is the potential consequence if Qualigen Therapeutics fails to regain compliance?
If Qualigen Therapeutics fails to regain compliance within the specified period, its common stock may be delisted from the Nasdaq Capital Market.
Filing Stats: 501 words · 2 min read · ~2 pages · Grade level 12.4 · Accepted 2024-08-05 16:10:37
Filing Documents
- form8-k.htm (8-K) — 34KB
- 0001493152-24-030244.txt ( ) — 203KB
- qlgn-20240802.xsd (EX-101.SCH) — 3KB
- qlgn-20240802_lab.xml (EX-101.LAB) — 33KB
- qlgn-20240802_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUALIGEN THERAPEUTICS, INC. Date: August 5, 2024 By: /s/ Michael S. Poirier Michael S. Poirier, Chief Executive Officer